{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:25Z","timestamp":1786977865764,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Real\u2010world data for treatment effectiveness and renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) are limited. Therefore, we aimed to evaluate treatment and renal outcomes of this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>\n                      We analyzed 834 patients with CHB previously treated with TDF for \u226512\u00a0months who were switched to TAF in routine practice at 13 US and Asian centers for changes in viral (HBV DNA\u00a0&lt;\u00a020\u00a0IU\/mL), biochemical (alanine aminotransferase [ALT]\u00a0&lt;\u00a035\/25\u00a0U\/L for male\/female), and complete (viral+biochemical) responses, as well as estimated glomerular filtration rate (eGFR; milliliters per minute per 1.73 square meters) up to 96\u00a0weeks after switch. Viral suppression (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) and ALT normalization (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.003) rates increased significantly after switch, with a trend for increasing complete response (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      <jats:sub>trend<\/jats:sub>\n                      = 0.004), while the eGFR trend (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      <jats:sub>trend<\/jats:sub>\n                      \u00a0&gt;\u00a00.44) or mean eGFR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&gt;\u00a00.83, adjusted for age, sex, baseline eGFR, and diabetes, hypertension, or cirrhosis by generalized linear modeling) remained stable. However, among those with baseline eGFR\u00a0&lt;\u00a090 (chronic kidney disease [CKD] stage \u22652), mean eGFR decreased significantly while on TDF (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.029) but not after TAF switch (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.90). By week 96, 21% (55\/267) of patients with CKD stage 2 at switch improved to stage 1 and 35% (30\/85) of CKD stage 3\u20105 patients improved to stage 2 and 1.2% (1\/85) to stage 1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, we observed continued improvement in virologic response, ALT normalization, and no significant changes in eGFR following switch to TAF from TDF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.31793","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T18:01:10Z","timestamp":1615485670000},"page":"656-666","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice"],"prefix":"10.1097","volume":"74","author":[{"given":"Hidenori","family":"Toyoda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Ogaki Municipal Hospital,Ogaki,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Leong","sequence":"additional","affiliation":[{"name":"Henry D. Janowitz Division of Gastroenterology,Mt. Sinai Health System,New York,NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-7760","authenticated-orcid":false,"given":"Charles","family":"Landis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,University of Washington,Seattle,WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunamasa","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,St. Marianna University School of Medicine,Kawasaki,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q.","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Department of Medicine,National University Hospital,Singapore"},{"name":"Department of Medicine,Yong Loo Lin School of Medicine,National University of Singapore,Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,University of Washington,Seattle,WA"},{"name":"University of Washington,Seattle,WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Xin Zi","family":"Quek","sequence":"additional","affiliation":[{"name":"Department of Medicine,National University Hospital,Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Saiseikai Niigata Hospital,Niigata,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yokohama","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine,Osaka Medical College,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Chuma","sequence":"additional","affiliation":[{"name":"Gastroenterological Center,Yokohama City University Medical Center,Yokohama,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[{"name":"Department of Hepatology,Kagawa Prefectural Central Hospital,Kagawa,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Uojima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Internal Medicine,Kitasato University School of Medicine,Sagamihara,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Senoo","sequence":"additional","affiliation":[{"name":"Department of Hepatology,Kagawa Prefectural Central Hospital,Kagawa,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansen","family":"Dang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hoang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Le","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Ogaki Municipal Hospital,Ogaki,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin N.","family":"Thin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Tran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Chien","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2915-7875","authenticated-orcid":false,"given":"Akira","family":"Asai","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine,Osaka Medical College,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Fukunishi","sequence":"additional","affiliation":[{"name":"Premier Development Research of Medicine,Osaka Medical College,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey","family":"Cheung","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"},{"name":"Division of Gastroenterology and Hepatology,The Palo Alto Veterans Affairs Health Care System,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0994-4932","authenticated-orcid":false,"given":"Seng Gee","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Department of Medicine,National University Hospital,Singapore"},{"name":"Department of Medicine,Yong Loo Lin School of Medicine,National University of Singapore,Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy N.","family":"Trinh","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology,San Jose,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University Medical Center,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"hep31793-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"hep31793-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31793-bib-0004-20250824","article-title":"Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study","volume":"9","year":"2019","journal-title":"BMJ Open"},{"key":"hep31793-bib-0005-20250824","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"hep31793-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta\u2010analysis","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep31793-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.cgh.2018.08.037","article-title":"Changes in renal function in patients with chronic HBV infection treated with tenofovir disoproxil fumarate vs entecavir","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31793-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/liv.14009","article-title":"Hepatitis B and renal function: a matched study comparing non\u2010hepatitis B, untreated, treated and cirrhotic hepatitis patients","volume":"39","year":"2019","journal-title":"Liver Int"},{"key":"hep31793-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep31793-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide versus tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep31793-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2147\/DDDT.S126742","article-title":"Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy","volume":"11","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"hep31793-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg\u2010negative chronic hepatitis B virus infection: a randomised, double\u2010blind, phase 3, non\u2010inferiority trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31793-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","year":"2019","journal-title":"J Viral Hepat"},{"key":"hep31793-bib-0014-20250824","article-title":"Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31793-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double\u2010blind, phase 3, multicentre non\u2010inferiority study","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31793-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1111\/jgh.14686","article-title":"Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate","volume":"34","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"hep31793-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"key":"hep31793-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","year":"2005","journal-title":"Kidney Int"},{"key":"hep31793-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","year":"1976","journal-title":"Nephron"},{"key":"hep31793-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","year":"2006","journal-title":"Ann Intern Med"},{"key":"hep31793-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","article-title":"The aging kidney: physiological changes","volume":"17","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"hep31793-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on\u2010treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep31793-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","article-title":"An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia","volume":"55","year":"2020","journal-title":"J Gastroenterol"},{"key":"hep31793-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1681\/ASN.2010090960","article-title":"Racial and ethnic differences in kidney function decline among persons without chronic kidney disease","volume":"22","year":"2011","journal-title":"J Am Soc Nephrol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31793","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:10:40Z","timestamp":1756077040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31793","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"2020-09-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}